Renovaro (RENB) Competitors $0.36 -0.01 (-3.64%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RENB vs. CYRX, RNAC, TSVT, AQST, TSHA, ATXS, ATYR, ATAI, CMPS, and GLUEShould you be buying Renovaro stock or one of its competitors? The main competitors of Renovaro include Cryoport (CYRX), Cartesian Therapeutics (RNAC), 2seventy bio (TSVT), Aquestive Therapeutics (AQST), Taysha Gene Therapies (TSHA), Astria Therapeutics (ATXS), Atyr PHARMA (ATYR), Atai Life Sciences (ATAI), COMPASS Pathways (CMPS), and Monte Rosa Therapeutics (GLUE). These companies are all part of the "pharmaceutical products" industry. Renovaro vs. Cryoport Cartesian Therapeutics 2seventy bio Aquestive Therapeutics Taysha Gene Therapies Astria Therapeutics Atyr PHARMA Atai Life Sciences COMPASS Pathways Monte Rosa Therapeutics Cryoport (NASDAQ:CYRX) and Renovaro (NASDAQ:RENB) are both small-cap transportation companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, media sentiment, analyst recommendations, community ranking, valuation, risk and institutional ownership. Do analysts rate CYRX or RENB? Cryoport currently has a consensus price target of $11.67, suggesting a potential upside of 107.96%. Given Cryoport's stronger consensus rating and higher probable upside, analysts plainly believe Cryoport is more favorable than Renovaro.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cryoport 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Renovaro 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community prefer CYRX or RENB? Cryoport received 251 more outperform votes than Renovaro when rated by MarketBeat users. CompanyUnderperformOutperformCryoportOutperform Votes25165.88% Underperform Votes13034.12% RenovaroN/AN/A Does the media prefer CYRX or RENB? In the previous week, Cryoport had 7 more articles in the media than Renovaro. MarketBeat recorded 8 mentions for Cryoport and 1 mentions for Renovaro. Cryoport's average media sentiment score of 0.88 beat Renovaro's score of 0.38 indicating that Cryoport is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cryoport 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Renovaro 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility & risk, CYRX or RENB? Cryoport has a beta of 1.81, suggesting that its share price is 81% more volatile than the S&P 500. Comparatively, Renovaro has a beta of 0.59, suggesting that its share price is 41% less volatile than the S&P 500. Which has preferable earnings & valuation, CYRX or RENB? Renovaro has lower revenue, but higher earnings than Cryoport. Cryoport is trading at a lower price-to-earnings ratio than Renovaro, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCryoport$228.39M1.23-$99.59M-$2.49-2.25RenovaroN/AN/A-$80.65M-$0.93-0.39 Is CYRX or RENB more profitable? Renovaro has a net margin of 0.00% compared to Cryoport's net margin of -70.08%. Cryoport's return on equity of -13.35% beat Renovaro's return on equity.Company Net Margins Return on Equity Return on Assets Cryoport-70.08% -13.35% -6.43% Renovaro N/A -61.84%-48.07% Do insiders and institutionals have more ownership in CYRX or RENB? 92.9% of Cryoport shares are held by institutional investors. Comparatively, 71.4% of Renovaro shares are held by institutional investors. 10.1% of Cryoport shares are held by company insiders. Comparatively, 21.7% of Renovaro shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. SummaryCryoport beats Renovaro on 11 of the 16 factors compared between the two stocks. Remove Ads Get Renovaro News Delivered to You Automatically Sign up to receive the latest news and ratings for RENB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RENB vs. The Competition Export to ExcelMetricRenovaroPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$57.14M$6.25B$5.28B$7.36BDividend YieldN/A3.24%5.11%4.32%P/E Ratio-0.396.6921.6317.68Price / SalesN/A222.70371.0892.88Price / CashN/A65.6738.1534.64Price / Book0.695.776.373.94Net Income-$80.65M$142.01M$3.20B$247.45M7 Day Performance-13.21%2.88%1.79%0.48%1 Month Performance-55.29%-13.93%-9.41%-7.08%1 Year Performance-85.12%-12.36%9.61%-0.35% Renovaro Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RENBRenovaro0.5556 of 5 stars$0.36-3.6%N/A-84.8%$57.14MN/A-0.3920Gap DownCYRXCryoport2.6779 of 5 stars$5.49+2.8%$11.83+115.5%-67.0%$274.01M$228.39M-1.621,020Analyst ForecastGap DownRNACCartesian Therapeutics1.7275 of 5 stars$10.11+1.1%$42.14+316.8%-37.0%$261.92M$38.91M-0.1964Gap UpTSVT2seventy bio2.0587 of 5 stars$4.95flat$6.67+34.7%-0.3%$259.07M$37.86M-2.66440Short Interest ↓High Trading VolumeAQSTAquestive Therapeutics1.7607 of 5 stars$2.62-3.3%$10.57+303.5%-34.8%$259.04M$57.56M-5.82160Gap DownTSHATaysha Gene Therapies2.9789 of 5 stars$1.24+1.6%$6.63+434.3%-52.3%$254.20M$8.33M1.97180Gap DownATXSAstria Therapeutics2.4519 of 5 stars$4.50-3.4%$26.60+491.1%-62.4%$253.95MN/A-2.1530Positive NewsATYRAtyr PHARMA2.729 of 5 stars$2.85+8.8%$18.60+552.6%N/A$253.25M$235,000.00-3.0353Positive NewsATAIAtai Life Sciences2.9175 of 5 stars$1.27-3.1%$10.50+726.8%-32.9%$251.85M$308,000.00-1.5780Positive NewsCMPSCOMPASS Pathways2.5499 of 5 stars$2.70-0.4%$20.20+648.1%-63.7%$250.22MN/A-1.23120Positive NewsGLUEMonte Rosa Therapeutics2.9737 of 5 stars$4.05+2.5%$15.50+282.7%-32.6%$249.12M$75.62M-2.2190Short Interest ↓Positive NewsGap Down Remove Ads Related Companies and Tools Related Companies Cryoport Alternatives Cartesian Therapeutics Alternatives 2seventy bio Alternatives Aquestive Therapeutics Alternatives Taysha Gene Therapies Alternatives Astria Therapeutics Alternatives Atyr PHARMA Alternatives Atai Life Sciences Alternatives COMPASS Pathways Alternatives Monte Rosa Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RENB) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredMarkets in Chaos? Here’s What to Do.Wall Street's on edge with tariffs. And volatility? It's not slowing down. You've seen the headlines… Bu...Investors Alley | SponsoredCatastrophicThe losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.InvestorPlace | SponsoredTrump 2028 could be a “bonanza” for investorsAs you may have heard, Donald Trump is planning to run for a THIRD term in 2028. Recently he told NBC news ...Paradigm Press | SponsoredIf Gold Is ‘Stalling,’ Why Are Banks Hoarding Billions In Secret?Prosperity was something every American family could build, protect, and pass down. Because that's what legacy...Colonial Metals | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredCould this be my downfall?I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Renovaro Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Renovaro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
